Introduction: Neurological complications are, at the present time, considered among the most important causes of morbidity and mortality after heart surgery. We evaluated their importance and risk factors. Patients and Methods: We retrospectively reviewed 2,528 consecutive patients who underwent cardiopulmonary bypass in a single center. In each one, we attended to previous vascular risk factors, such as surgical and postoperative events. We considered four categories of neurologic outcome: (1) persistent neurological focal deficits, (2) stupor or coma, (3) temporary neurological focal deficits, and (4) seizures. We carried out univariant and multivariant statistical analysis, looking for predictors of adverse neurologic events. Results: Neurological complications occurred in 76 patients (3%); 36 of them (47%) had persistent neurological focal deficits, 18 (24%) stupor or coma, 18 (24%) temporary neurological focal deficits, and 27 (36%) seizures. Twenty-two patients with cerebral adverse outcomes died (29%), the overall mortality among the 2,528 cases being 5%. Predictors of risk were aortic aneurysm and aortic valve surgery, advanced age, female sex, and the use of intra-aortic balloon pump. A longer hospitalization time was noticed among patients with neurological side effects. Discussion: Neurological complications are common and serious after heart surgery, as we have noticed with this series, the largest up to now, according to our review of the literature. They increase perioperative mortality and hospitalization time. Neurological morbidity and risk factors in our study are similar to those previously published.

Keywords:
Cardiac surgery, Cardiopulmonary bypass, Neurological complications
1.
Mills SA: Cerebral injury and cardiac operations. Ann Thorac Surg 1993;56:S86–91.
2.
Mills SA, Prough DS: Neuropsychiatric complications following cardiac surgery. Semin Thorac Cardiovasc Surg 1991;3:39–46.
3.
Gilman SD: Neurological complications of open heart surgery. Ann Neurol 1990;28:475–476.
4.
Arom KV, Cohen DE, Strobl FT: Effect of intraoperative intervention on neurological outcome based on electroencephalographic monitoring during cardiopulmonary bypass. Ann Thorac Surg 1989;48:476–483.
5.
Fessatidis Y, Prapas S, Hevas A, Didilis V, Alotzeilat A, Missias G, Asteri T, Spyrou P: Prevention of perioperative neurological dysfunction: A six year perspective of cardiac surgery. J Cardiovasc Surg 1991;32:570–574.
6.
Coffey CE, Massey EW, Roberts KB, Curtis S, Jones RH, Pryor D: Natural history of cerebral complications of coronary artery bypass graft surgery. Neurology 1983;33:1416–1421.
7.
Heikkinen L: Clinically significant neurological disorders following open heart surgery. Thorac Cardiovasc Surg 1985;33:201–206.
8.
Zeilthofer J, Asenbaum S, Spiss C, Wimmer A, Mayr N, Wolner E, Deecke I: Central nervous system function after cardiopulmonary bypass. Eur Heart J 1993;14:885–890.
9.
Tuman KJ, Mc Carthy RP, Najafi H, Ivanovich AD: Differential effects of avanced age on neurologic and cardiac risk of coronary artery operations. J Thorac Cardiovasc Surg 1992;104:1510–1517.
10.
Roach GW, Kanchuger M, Mora Mangano C, et al: Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med 1996;335:1857–1863.
11.
Weintraub WS, Jones EL, Craver J: Determinants of prolonged length of hospital stay after coronary bypass surgery. Circulation 1989;80:276–284.
12.
Katz ES, Tunick PA, Rusinek H, et al: Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: Experience with intraoperative transesophageal echocardiography. J Am Coll Cardiol 1992;20:70–77.
13.
Kirklin JW, Barrat-Boyes BG: Hypothermia, circulatory arrest and cardiopulmonary bypass. Cardiac Surgery, ed 2. New York, Churchill Livingstone, 1993, pp 67–73.
14.
Shaw PJ, Bates D, Cartlidge EN, French JM, Heaviside D, Julian DG, et al: Neurologic and neuropsychological morbidity following major surgery: Comparison of coronary artery bypass and peripheral vascular disease. Stroke 1987;18:700–707.
15.
Treasure T, Smith PL, Newman S, Schneidau A, Joseph P, Ell P, Harrison MJ: Impairment of cerebral function following cardiac and other major surgery. Eur J Cardiothorac Surg 1989;3:216–221.
16.
Nevin M, Colchester AC, Adams S, Pepper JR: Evidence for involvement of hypocapnia and hypoperfusion in aetiology of neurological deficit after cardiopulmonary bypass. Lancet 1987;ii:1493–1495.
17.
Shaw PJ: The incidence and nature of neurological morbidity following cardiac surgery: A review. Perfusion 1989;4:83–92.
18.
Smith PL, Treasure T, Newman SP, Joseph P, Ell PJ, Scheneidau A, Harrison MJ: Cerebral consequences of cardiopulmonary bypass. Lancet 1986;1(8485):823–825.
19.
Wareing TH, Davila-Roman VG, Daily BB, Murphy SF, Schechtman KB, Barzilai B, Kouchoukos NT: Strategy for the reduction of stroke incidence in cardiac surgical patients. Ann Thorac Surg 1993;55:1400–1408.
20.
Trehan N, Mishra M, Dhole S, Mishra A, Karlekar A, Kohli VM: Significantly reduced incidence of stroke during coronary artery bypass grafting using transesophageal echocardiography. Eur J Cardiothorac Surg 1997;11:234–242.
21.
Rorick MB, Frulan A: Risk of cardiac surgery in patients with prior stroke. Neurology 1990;40:835–837.
22.
Beall AC, Jones JW, Guinn GA, Svensson LG, Nahas C: Cardiopulmonary bypass in patients with previously completed stroke. Ann Thorac Surg 1993;56:1440–1441.
23.
Zisbrod Z, Rose DM, Jacobowitz IJ, Kramer M, Acinapura AJ, Cunningham JN Jr: Results of open heart surgery in patients with recent cardiogenic embolic stroke and central nervous system disfunction. Circulation 1987;76:109–112.
24.
Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, Tarazi R, Shroyer AL, Sethi GK, Grover FL, Hammermeister KE: Atrial fibrillation after cardiac surgery: A major morbid event? Ann Surg 1997;226:501–511.
25.
Carrascal Y, Guerrero AL, Maroto L, López-Gude MJ, Rufilanchas JJ: Complicaciones neurológicas tras cirugía extracorpórea. Rev Neurol (Barc) 1997;25:1278–1284.
26.
Christenson JT, Simonet F, Badel P, Schmuziger M: Evaluation of preoperative intra-aortic balloon pump support in high risk coronary patients. Eur J Cardiothorac Surg 1997;11:1097–1103.
27.
Chow G, Roberts IG, Fallon P, Onoe M, Lloyd-Thomas A, Elliott MJ, Edwards AD, Kirkham FJ: The relation between arterial oxygen tension and cerebral blood flow during cardiopulmonary bypass. Eur J Cardiothorac Surg 1997;11:633–639.
28.
Rooney SJ, Pagano D, Bognolo G, Wong C, Bonser RS: Aprotinin in aortic surgery requiring profound hypothermia and circulatory arrest. Eur J Cardiothorac Surg 1997;11:373–378.
29.
Lemmer JH, Dilling EW, Morton JR, Rich JB, Robiseck F, Bricker DL, Hantler CH, et al: Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659–1668.
30.
Umbrain V, Christiaens F, Camu F: Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994;8:198–201.
31.
Libman RB, Wurchowski E, Neystat M, Barr W, Gelb S, Graver M: Stroke associated with cardiac surgery. Arch Neurol 1997;54:83–87.
32.
Newman MF, Wolman R, Kanchuger M, Marshall K, Mora-Mangano C, Roach G, Smith R, et al: Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Circulation 1996;94(suppl II):II74–II80.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.